Clinical Trial Update: Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects [Phase 4]

View source ↗

Summary

Phase 4 study update reporting the single-dose pharmacokinetics of Suboxone in subjects with hepatic impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment
• Hepatitis C
• Liver Disease

Drugs mentioned

• SUBOXONE (buprenorphine hydrochloride, naloxone hydrochloride)

Snippet

Sponsor: Indivior Inc. | Conditions: Hepatic Failure, Hepatic Impairment | Phase 4 | Status: COMPLETED | Results posted: 2016-10-24